SureTrader SureTrader
Home > Boards > US Listed > Mining/Resources >

VolitionRX Limited (VNRX)

Add VNRX Price Alert      Hide Sticky   Hide Intro
Search This Board:
Last Post: 5/10/2016 6:56:50 AM - Followers: 27 - Board type: Free - Posts Today: 0

VolitionRx Ltd. is a life sciences company focused on bringing to market its inexpensive, accurate, and scalable cancer detection blood tests. The company intends to use its NuQ® suite of products to fill a looming void in cancer diagnostic testing, for which there currently is only one blood test in common clinical use.

NuQ® is based on VolitionRx's proprietary Nucleosomics® technology, capable of measuring and identifying nucleosome structures in the blood. The company has secured strong intellectual property protection for its products, further strengthened by patent applications in the United States, Europe and worldwide. Following ongoing clinical trials and regulatory approval, VolitionRx will market its diagnostic and screening tests for individual cancers under the NuQ® brand.

The company is currently conducting clinical trials for its first product, a diagnostic test for colorectal cancer. Colorectal cancer is the third most common cancer in the United States - current tests are expensive, invasive and unpleasant, resulting in a significant need for an improved alternative for colorectal diagnoses.

VolitionRx's primary office and laboratory are based in Namur, Belgium, from which the company's strong team of professionals spearhead corporate initiatives. The company's executive management team is further supported by a scientific advisory board staffed with senior scientists from around the world, as well as a highly experienced board of directors.


Investment Highlights

  • Developing Revolutionary Cancer Diagnostic Tests
  • Current Focus on Colorectal Cancer
  • Proprietary Nucleosomics® Technology
  • Tests Inexpensive to Produce
  • Experienced Management, Advisory Board
  • Strong Patent Protection for all Key Technologies
  • Tests Based on Cutting-Edge Science


Nucleosomics® Technology

VolitionRx’s proprietary Nucleosomics® technology is an epigenetic profiling platform for the detection of histone variants and post-translational modifications in intact nucleosomes. The NuQ® range of immunoassays is designed to meet the needs of the rapidly expanding epigenetics research market.

VolitionRx is developing two types of tests based on the Nucleosomics® technology:

  • Cancer screening tests: tests given to an entire population (e.g. all 50-year-olds). Commonly given cancer screening tests include colonoscopies for colorectal cancer and Pap smear tests for cervical cancer.
  • Cancer diagnostic tests: tests given to a patient when they indicate cancer-like symptoms to a healthcare professional. Common cancer diagnostic tests include scans and biopsies. VolitionRx has developed a range of around 20 individual assays, each of which identifies and quantifies a particular nucleosome structure.

A panel of assays encompassing the four-five best assays for identifying a particular cancer will be selected to make up a single cancer test. Taken as a whole, the test will be able to identify whether the patient has that specific cancer. The test panel will be administered to patients as a single test for which only one small blood sample will need to be drawn.

VolitionRx is currently optimizing the individual panels for each cancer as the company continues to discover methods of detecting further nucleosome structures.


How it Works

VolitionRx’s NuQ® range of products is based on the Nucleosomics® platform, which identifies and measures nucleosome structures in cell culture, serum, plasma or other biofluids.

  • DNA is compacted as protein complexes in a “beads on a string” structure.
  • Nucleosome “beads” consist of DNA wrapped around a core of histone proteins.
  • Each core consists of four pairs of variants of H2A, H2B, H3 and H4 histones.
  • Histones and the DNA are subject to a variety of post translational modifications.
  • Various proteins interact with nucleosomes to modulate gene expression.
  • Each NuQ® ELISA captures intact nucleosomes and labels a specific feature.

VolitionRx’s Nucleosomics tests are protected by worldwide patent applications filed initially in Europe and the United States of America.


Current Products

Cancer for years has been considered a genetic disease. However, in the last decade, several epigenetic deregulations have been associated with genetic alteration-causing carcinogenesis.

Epigenetic changes such as DNA methylation and histone modifications, as well as deregulation of epigenetics regulators, are now well-recognized as mechanism implicated in the malignant phenotype. VolitionRx provides a wide variety of kits to analyze these epigenetic modifications.


Nucleosomics® Accessing the Epigenome

The company’s NuQ® range of research uses only epigenetic research tools, and is available to life science researchers in a familiar and accessible format – the simple immunoassay.

Key features: NuQ® assays are robust, reliable and reproducible. No specialist equipment or training is required and simplicity of use and data interpretation is at the heart of VolitionRx’s standard immunoassay format.


NuQ®-X: DNA modification kits

VolitionRx’s NuQ-X® range of DNA modification kits offers a validated tool to aid researchers in their DNA modification studies. DNA contains two modified cytosine bases: 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC). 5mC is an epigenetic modification involved in gene regulation, mammalian X-chromosome inactivation, chromatin structure, differentiation, cancer development as well other complex diseases and aging. 5hmC was discovered more recently but has already been found in many cell types and tissues. Its role is less known, but may contribute to the demethylation of DNA and to the dynamic of the chromatin structure.

Areas of Research: NuQ®-X DNA modification kits may be of interest to researchers working in the following fields:

  • Chromatin Structure & Function
  • Epigenetic Regulators
  • Infectious Disease
  • Inflammatory Disease
  • Oncology
  • Stem Cells
  • Apoptosis


NuQ®-V: Histone variant kits

VolitionRx’s NuQ®-V range of histone variant kits can be used to analyze the global level of histone variants.

Nucleosomes, the basic repeat element of chromatin, consist of DNA wrapped around an octamere of histone proteins (H2A, H2B, H3, H4). Apart from the major core histone, there is a repertoire of histone variants. These variants confer distinct properties to the nucleosomes and have emerged as key players in regulating chromatin structure and dynamics.

Areas of Research - NuQ®-V histone variant kits may be of interest to researchers working in the following fields:

  • Chromatin Structure & Function
  • Inflammatory Disease
  • Oncology
  • Stem Cells


NuQ®-M: Histone modification kits

VolitionRx’s NuQ®-M range of histone modification kits is dedicated to the analysis of different histone modifications.

Histones may be subjected to a wide variety of epigenetic modifications such as phosphorylation, acetylation and methylation at specific residues. These post-translational modifications occur primarily on the N-terminal tail of histones. Histone modifications are described in numerous normal or disease-related processes.

Areas of Research - NuQ®-M modification kits may be of interest to researchers working in the following fields:

  • Chromatin Structure & Function
  • Epigenetic Regulators
  • Inflammatory Disease
  • Oncology
  • Stem Cells


NuQ®-A: Adduct kits

VolitionRx’s NuQ®-A range of adduct kits is available for the study of several different nucleosome-protein adducts. Nucleosomes are potentially associated with numerous other proteins or protein complexes, each with a different function onto chromatin.

NuQ®-A products offer analysis of the presence of hormone receptors such as oestrogen, progesterone or androgen receptor; the High Mobility Group Box protein 1 (HMGB1), or the Histone-lysine N-methyltransferease EZH2.

Areas of Research - NuQ®-A Adduct Kits may be of interest to researchers working in the following fields:

  • Epigenetic Regulators
  • Infectious Disease
  • Inflammatory Disease
  • Oncology
  • Stem Cells
  • Apoptosis



Results & Collaborations

A positive result occurs when above the normal range, calculated by the standard diagnostic method (mean ± 2 standard deviations of the mean).

Results presented at Clinical Genomics and Informatics Europe, Dec 2013 - Preliminary findings from CHU Dinant Godinne | UCL Namur Hospital in Belgium:

  • Colorectal cancer two-assay panel test
  • 85% detection rates at 85% specificity
  • 50% of precancerous polyps detected

Results presented at CNAPS conference, Nov 2013 - Colorectal cancer single-assay test:

  • 75% of cancers detected, 70% specificity (90 patients, one single assay); data reconfirmed on further 113 patients

Nov 2012: Preliminary results:

  • Colon: 76% of cancers detected at 90% specificity
  • Breast: 96% of cancers detected at 90% specificity
  • Lung: 100% of cancers at 79% specificity

Ongoing Collaborations:

Hvidovre Hospital

  • Analysis: start 2013, end 2014
  • Number of patients: 4,800

Hvidovre Hospital

  • Analysis: to start 2014, end 2015
  • Number of patients: 11,000

Mont Godinne

  • Analysis of samples underway
  • Number of patients: 250

Bonn University, Germany

  • Start date following collection
  • Number of patients; 2,000


Colorectal Screening Market

Colorectal cancer is the third most commonly diagnosed cancer and the third leading cause of cancer death worldwide, following lung and breast cancers.

  • There is currently only one blood test to screen for cancer (the PSA for prostate cancer) in common clinical use
  • Around 12.7 million new cancer cases are diagnosed worldwide every year
  • Early detection is integral to survival and better patient outcomes
  • Currents tests often have many false negatives/positives

Despite recommendations for more routine screening, less than 40% of individuals aged 50+ report having received colorectal cancer testing consistent with current guidelines - the lag is largely due to the high costs and invasiveness of most screening procedures.

Current CRC diagnostics:

  • Colonoscopy – invasive and expensive
  • FIT/FOBT faecal-based tests – unpleasant and poor detection rate for precancerous polyps

Blood is better for early diagnosis:

  • FIT compliance only 30-60%
  • PSA (prostate cancer blood test) compliance at least 80% - even though the test isn’t very accurate
  • 95% of people would rather take a blood test than a colonoscopy

The low-cost and minimally invasive nature of diagnostic blood tests encourages much higher uptake. One study shows annual prostate cancer screening compliance at higher than 80%. When VolitionRx’s NuQ® blood test is made publically available, the company believes that higher uptake could be very likely.

Additionally, if the research team continues to identify at least 50% of polyps, this could also have vast implications for diagnosing earlier-stage colorectal cancers.


Growth Strategy

VolitionRx is broadening the development and production of a full suite of epigenetic products under the “NuQ®” brand name, based on Nucleosomics® technology. The company has started clinical validations and trials to begin the process of obtaining appropriate approvals for clinical (patient) use (e.g. FDA approval in the USA, CE Marking in Europe).

The product rollout strategy is planned to take place over four stages: simple 96-well ELISA for research and first clinical sales; large scale hospital laboratory equipment; smaller point-of-care tests for use in oncologists’ offices; and finally small disposable tests for use by MD or home use.

Commercialization Strategy

  • Revenues through direct sales, sales partners, and distribution agreements.
  • Each product will initially be sold to the research market or via CLIA while going through regulatory approvals processes for clinical (patient) products in Europe (CE mark) and USA (FDA approval).
  • Aims to address the need for inexpensive (costing around $2 per patient to produce), early, accurate, and scalable cancer diagnostics with its NuQ® suite of products.
  • NuQ® is based on proprietary Nucleosomics® technology - the measurement and identification of nucleosome structures in the blood.


Revenue & Market Potential

Research market

  • VolitionRx expected to enter market Q1 2014.
  • Initial manufacturing cost $100-$140 per 96-well ELISA plate. Selling price is €795 – €995 (approximately $1025 - $1285 on current exchange rates).
  • Estimated size of total research market: $3 million-$5 million per year.

Centralized laboratory clinical market

  • VolitionRx expected to apply for European regulatory approval in 2014.
  • The cost to manufacture and supply the test will be under $2 per patient, with retail price to the laboratory estimated at $40 per patient (the laboratory will charge a higher price to the patient).
  • Estimated size of total clinical laboratory test market: $450+ million per year.

Point-of-care clinical market

  • Volition estimates entry to market after 2015.
  • Delay due to need to adapt tests to small instrument, and to demonstrate success in centralized market before adoption by doctors.

Self-test clinical market

  • Cost to manufacture approximately $5-$6 per test, sales price for end user estimated to be $30-$40.
  • Potential total market size for NuQ® self-tests is more than $1 billion annually, based on 30 million test sales worldwide annually.


Management Team

VolitionRx has put together a proven team that provides exemplary leadership backed by a unique blend of scientific management and business expertise.


Cameron Reynolds - President & Chief Executive Officer

Cameron Reynolds has more than 17 years of entrepreneurial executive expertise in mining and biotechnology companies. He has strong experience in the management, structuring and strategic planning of start-up companies, as well as in securing financing.


Malcolm Lewin - Chief Financial Officer & Treasurer

Malcolm Lewin has a strong background in finance and accounting both for public and private companies alike. He qualified as a chartered accountant with Coopers & Lybrand in 1976. Lewin’s background includes finance director of several companies with interests worldwide.


Jason Terrell MD - Chief Medical Officer & Head of U.S. Operations

Dr. Jason Terrell has a strong grounding in both medicine and more specifically in diagnostics. He currently owns and operates multiple diagnostic laboratories in Texas within the Any Lab Test Now franchise, and has also served as a National Franchise Corporate Medical Director for Any Lab Test Now, giving him oversight of more than 70 franchises in 14 states. Dr. Terrell holds medical licenses in 14 states across the U.S.


Rod Rootsaert - Secretary

Rodney Rootsaert has more than six years of experience in providing corporate, legal and administrative services to start-up companies through Mining House Ltd., of which Rootsaert has been a director since 2007.


Thomas Bygott - Sales & Marketing Director

Tom Bygott is a qualified bioinformatician with more than 12 years of experience in sales and marketing for technology companies. Bygott started his career with the Australian electronics company AWA as a business analyst conducting reviews of their Traffic division and electronics factory, later becoming a Marketing Executive for their Aerospace division.


Scientific Executives

Jake Micallef PhD MBA - Chief Scientific Officer, Belgian Volition

Dr. Jacob Micallef has 20 years of experience in research and development and in the management of early stage biotechnical companies, including the manufacture of biotechnology products and the establishment of manufacturing operations. Dr. Micallef gained this experience while working for the World Health Organization (WHO) over a 10-year period from 1985.


Mark Eccleston, PhD - Chief Scientific Officer, HyperGenomics

Dr. Mark Eccleston is a biotechnology entrepreneur with more than 18 years of experience in the sector, both in academia and in industry. His career includes experience from various roles, including a program management position, CEO, chief scientific officer and consultant.


VolitionRx Ltd.
Belgian Volition SA – Centre Technologique
Rue du Seminaire, 20A
BE – 5000 Namur
Singapore 228208
Phone: +32 (0) 81 72 56 50

3645 Marketplace Blvd.
Suite 130-280
Atlanta, GA 30344
Phone: (404) 941-8975



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
VNRX News: VolitionRx Limited Announces Exercise of Over-Allotment Option by Underwriter 10/21/2016 11:34:00 AM
VNRX News: Securities Registration: Employee Benefit Plan (s-8) 10/14/2016 04:17:57 PM
VNRX News: Current Report Filing (8-k) 10/11/2016 04:39:38 PM
VNRX News: Data Presented at ESMO 2016 Demonstrates that VolitionRx Limited's Novel Blood Test for Colorectal Cancer Potentially Reduces... 10/11/2016 08:30:00 AM
VNRX News: Statement of Changes in Beneficial Ownership (4) 10/06/2016 12:32:55 PM
#103   Hi, guys! turola 05/10/16 06:56:50 AM
#102   VolitionRx Talks With MicroCapClub About Revolutionizing Cancer Diagnostics MikeDDKing 04/14/16 10:48:09 PM
#101   VolitionRx Initiates Prostate Cancer Study in Collaboration with MikeDDKing 02/02/16 06:46:55 PM
#100   Rodman and Renshaw initiated coverage on 2/1/16 with MikeDDKing 02/02/16 06:45:20 PM
#99   VolitionRx Receives International ISO Certification for Quality Management MikeDDKing 02/02/16 06:43:57 PM
#98   VolitionRx Releases Annual Shareholder Update Letter MikeDDKing 02/02/16 06:43:04 PM
#97   VNRX was a recent addition to the SwingTrade MikeDDKing 02/02/16 06:40:44 PM
#96   Is 420i under contract by this Company ? Condor65 01/09/16 09:48:27 AM
#95   Hearing contrary opinions is important, and can be ghouyou 12/07/15 08:14:44 PM
#94   VNRX is proven and will receive fast track rodman 12/07/15 02:19:04 PM
#92   VNRX is a huge SCAM. Beware folks DeeezNuuuts 11/16/15 01:11:42 PM
#91   Well it happened drifted down to 3.59 and rodman 11/04/15 06:22:54 PM
#90   Agreed but I still see it drifting to rodman 10/23/15 11:51:54 AM
#89   VNRX: Could NuQ Become Gold Standard for Pancreatic Cancer? JustGoLong 10/14/15 09:39:21 AM
#88   And watch it drop to the 3.70's and rodman 09/21/15 10:00:52 AM
#87   I sell 5000 4,67 for take mcur Lestatk 09/21/15 04:50:56 AM
#86   Sub 4's before this one heads back up rodman 09/20/15 12:38:31 PM
#85   Vnrx go to the moon Lestatk 09/09/15 09:39:56 AM
#84   Big day for VNRX...up 10%! Updated results JustGoLong 09/08/15 03:42:28 PM
#83   Tank for the New i keep vnrs for Lestatk 07/22/15 08:33:28 AM
#82   Compvany still had 11 million in the bank rodman 07/21/15 11:46:51 AM
#81   I keep my position for 3 years but Lestatk 07/19/15 05:43:18 PM
#80   Hello no News? Lestatk 07/19/15 05:40:13 PM
#79   Opened at 3.79 and the short sellers trying rodman 06/16/15 05:14:14 PM
#78   Getting more interesting from here up! AND down! rodman 06/15/15 04:53:03 PM
#77   All hype or is the $4. pps a rodman 06/07/15 10:48:46 AM
#76   I am a risk taker for better or rodman 06/05/15 03:58:51 PM
#75   I play long term good article in belgium Lestatk 06/04/15 04:39:19 PM
#74   Likely the pps ran up from hype of rodman 06/03/15 10:02:17 AM
#73   Vnrx go ?? Lestatk 06/02/15 05:20:48 PM
#72   Updating the pps movement for the board the rodman 06/02/15 12:43:10 PM
#71   Be conscious that this is a very young rodman 05/20/15 03:37:24 PM
#70   Hello roman tank for information my position 10000 Lestatk 05/09/15 01:30:28 PM
#69   VolitionRx Schedules First Quarter 2015 Earnings Conference Call rodman 05/06/15 09:42:24 AM
#68   Research is done and validated but for the rodman 05/03/15 03:26:37 PM
#67   here long and strong volition great future for Lestatk 05/02/15 06:31:38 AM
#66   Time to market for most product or services rodman 04/12/15 09:45:00 AM
#65   New to THIS board then start here......Many will rodman 04/04/15 04:50:04 PM
#64   Welcome to the VolitionRX I-Hub message board. Open rodman 03/22/15 11:31:09 AM
#63   Fair value of $6.70 may fall sooner then rodman 03/17/15 10:15:14 AM
#62   VNRX to ring the DJ opening bell Wednesday rodman 03/09/15 04:18:17 PM
#61   The officers and board members are world heatlh rodman 03/02/15 01:03:14 PM
#60   Here is an almost paradigm shift (if I rodman 02/27/15 09:29:03 AM
#59   Patent acquisition puts VolitionRX in prime position..... rodman 02/26/15 10:13:12 AM
#58   Learned my lesson in at 2.30 sold at rodman 02/07/15 11:56:21 AM
#57   VNRX moved from the OTC to NYSE AMEX: Renee 02/06/15 04:22:28 PM
#56   A Doctor friend advised me to review this rodman 10/15/14 03:01:54 PM
#55   VNRX broadens its research to other cancers: stealthways 10/12/14 12:19:44 AM
#54   $VNRX DD Notes ~ stocktrademan 10/02/14 11:04:07 AM
#53   $1,189,000 capital raised per Form D IPO$ 09/26/14 10:15:33 AM